(Date:6/30/2009)...n two recent COPD studies sponsored by DEY LP, PAR...a and Ultra II) were used to show that nebulized f....) improves pulmonary function. , , "We are pl...exclusive nebulizer systems for recent studies com...d et al. used an open-label crossover design allow...
(Date:6/30/2009).../ -- Cephalon, Inc. (Nasdaq: CEPH ) today announ...Application (sNDA) to the U.S. Food and Drug Admin...(armodafinil) Tablets [C-IV] for the indication of...leepiness associated with jet lag disorder resulti...acute condition that occurs when a person,s intern...
(Date:6/30/2009)...RNewswire/ -- , - "Study Could Have Major I... to Infertility Treatment" , New data from ...s,European Society of Human Reproduction and Embr...arameters of the simulation model used, the in vit...purified human menopausal,gonatropin or HP-hMG) o...
(Date:6/29/2009)...wswire/ -- Pioneering therapeutic trials to inves...on (DBS) in hard-to-treat depression, obsessive-...are underway at multiple medical centers around th...sue of Mayo Clinic Proceedings . "Deep brai...ontrolling movement disorders," according to the r...
Breaking Medicine Technology:PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 3Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 4New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 2New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 3New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 4Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 2Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 3WallSt net Announces Upcoming Interview With CEO Of Immunosyn Corporation 1800 1WallSt net Announces Upcoming Interview With CEO Of Immunosyn Corporation 1800 2WallSt net Announces Upcoming Interview With CEO Of Immunosyn Corporation 1800 3International Diabetes Experts Call for Stepped Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact 1798 1International Diabetes Experts Call for Stepped Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact 1798 2International Diabetes Experts Call for Stepped Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact 1798 3International Diabetes Experts Call for Stepped Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact 1798 4Histochemistry is the golden standard in the diagnosis of carcinosarcomas 6313 1Largest study to investigate risk factors of autism to begin enrolling families 1211 1Largest study to investigate risk factors of autism to begin enrolling families 1211 2...une 05, 2007 /PRNewswire/ -- , Professor Home said...ppointing and,misleading in that they disregarded ...nt to patients and physicians. Most,significantly ...e,of any increase in cardiovascular death or death...T: Professor Philip Home, (44) 778-525-1736 , Ter...
...mcg dosed every two weeks achieved an SVR rate at,...analysis), with,more favorable quality-of-life sco...irstCall/ -- Human,Genome Sciences, Inc. today ann...inical trial of Albuferon(R) (albinterferon alfa-2...e patients with,genotype 1 chronic hepatitis C. Th...
Other Medicine Technology:Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 2Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 3Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 4Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 6Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 7Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 8(Date:7/2/2009)...nology Institute (BTI) have made a novel discovery...ecule" (FAIM), protects both immune and liver cell...heir research is published in the current journal ...ts, Jianxin Huo, Ph.D., and Shengli Xu, Ph.D., als...ipulated for clinical application and proposed the...
(Date:7/2/2009)... Recent news reports have highlighted the importan...icians meet high standards in their chosen area of...cal Specialties (ABMS), which coordinates and assi...op and implement educational and professional stan...ician specialists. Certification by an ABMS Membe...
(Date:7/2/2009)... Pro-life forces won an important battle yesterday...te law regulating that abortion centers must prope...(also known as the "abortion pill") in order to pr...The ruling came in Rogers v. Planned Parenthood ,...equiring that those administering RU-486 comply wi...
(Date:7/2/2009)...in Washington, D.C. , , ARLINGTON, Texas, July...rces has received the Best Employers for Healthy ... on Health. , , (Logo: http://www.newscom.co...e award recognizes the nation,s leading corporatio...workplace and for helping employees and their fami...
Breaking Medicine News(10 mins):Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 320 g MVR knife. Dimensions: 31.8 mm x 1.18 mm x 2.7 mm.
Full Handle Laseredge Spoon Blade Knife, 3.0 mm angled double bevel. Blade dimension: 11.0 mm (L) x 3.0 mm (W). Cut: 320.
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.2 mm x 4.0 mm.
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm.
Medicine Products: